AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 301 min read$DFTX

Sullivan Mark sold $514K of DFTX

Sullivan Mark (Chief Legal Officer) sold 14,051 shares of Definium Therapeutics, Inc. (DFTX) at $36.57 ($0.51M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sullivan Mark
Published Sep 30, 2026, 1:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DFTX
Bearish
medium confidence
Mentioned
$DFTX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DFTXBearishLow
01

Why it matters

Provides fresh, primary data on insider activity, useful for short-term sentiment assessment.

02

Market read

Insider sale may cause slight short-term price pressure; limited broader market relevance.

03

What to watch

Potential upcoming clinical data or financing events could offset sell pressure.

Relevance 4/10Novelty 5/10Timing: post-market today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$DFTXBearishMedium confidence
Context

Chief Legal Officer sold 14,051 shares for $513,845 via a 10b5-1 plan, reducing his stake.

Expected impact

likely downward pressure as market prices in the insider sell

Evidence & confidence

C-level insider sale of over $500k, though modest, can be interpreted as a bearish signal.

Market effects

Sector

Minimal impact on biotech sector; isolated insider transaction.

Regional

Negligible effect on broader market.

Global

None

Counterpoint

What could challenge this read

The sale may be routine liquidity, not a bearish indicator.

Key entities

  • company
    Definium Therapeutics, Inc.

    Biotech firm listed under ticker DFTX.

  • person
    Sullivan Mark

    Chief Legal Officer of Definium Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DFTX insider trading history →

Related articles

SEP 23
$DFTXHighAI 9/10

Definium Therapeutics at TD Cowen summit: phase iii data lift dt120

Definium Therapeutics (DFTX) presented phase III data for DT120, showing statistically significant results in treating generalized anxiety disorder and major depressive disorder. The drug demonstrated placebo-adjusted improvements of 5.4, 5.1, and 8.1 points in respective studies, with rapid clearance. The company is preparing for pre-NDA talks with the FDA to discuss filing strategies. Response and remission rates were lower than phase II but still clinically meaningful.

investing.com2 min
SEP 20
$DFTXMedAI 8/10

Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for its LSD-based anxiety drug, DT120. The trial showed a 5.1-point improvement over placebo, similar to its previous trial. Psychedelic stocks often move together, and Definium's success could impact the broader sector. Hedge fund holdings of DFTX have increased, indicating growing institutional confidence.

yahoo.com2 min
SEP 19
$DFTXHighAI 9/10

Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study

Definium Therapeutics (DFTX) reported positive Phase III results for DT120 in treating anxiety, with 32% of patients showing significant improvement vs. 14% on placebo. The drug was well-tolerated, and the company plans to meet with the FDA in Q4, aiming for an NDA submission in early 2027. Definium has $1.1B in cash and is preparing for commercialization.

finance.yahoo.com2 min
SEP 19
$DFTXHighAI 9/10

Definium Therapeutics (DFTX) Posts Another Positive Phase 3, Is The Stock Still A Bargain?

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder. The stock has surged 184.53% year-to-date, with a fair value estimate of $71.65, suggesting a 46% undervaluation. The company faces risks due to its pre-revenue status and reliance on DT120's success, with key Phase 3 readouts expected in 2026.

simplywall.st3 min
SEP 17
$DFTXMed

DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?

Definium Therapeutics (DFTX) and Compass Pathways (CMPS) are in focus due to a White House push to accelerate psychedelic therapy research. Both companies are developing late-stage psychedelic therapies for psychiatric conditions. DFTX has a 62% upside with a $36.67 price target, while CMPS has a 227% upside with a $21.75 target. Both companies welcomed the executive order and highlighted their ongoing clinical trials.

stocktwits.com2 min